 Lupus Erythematosus, Systemic
"Lupus Erythematosus, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Descriptor ID |
D008180
|
| MeSH Number(s) |
C17.300.480 C20.111.590
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lupus Erythematosus, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Lupus Erythematosus, Systemic".
This graph shows the total number of publications written about "Lupus Erythematosus, Systemic" by people in this website by year, and whether "Lupus Erythematosus, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1997 | 2 | 0 | 2 | | 1999 | 2 | 0 | 2 | | 2001 | 1 | 2 | 3 | | 2002 | 3 | 2 | 5 | | 2003 | 2 | 1 | 3 | | 2004 | 6 | 3 | 9 | | 2005 | 5 | 0 | 5 | | 2006 | 6 | 1 | 7 | | 2007 | 4 | 1 | 5 | | 2008 | 6 | 0 | 6 | | 2009 | 6 | 1 | 7 | | 2010 | 7 | 1 | 8 | | 2011 | 4 | 2 | 6 | | 2012 | 7 | 0 | 7 | | 2013 | 5 | 2 | 7 | | 2014 | 6 | 3 | 9 | | 2015 | 2 | 0 | 2 | | 2016 | 7 | 2 | 9 | | 2017 | 4 | 1 | 5 | | 2018 | 5 | 2 | 7 | | 2019 | 8 | 0 | 8 | | 2020 | 4 | 1 | 5 | | 2021 | 4 | 3 | 7 | | 2022 | 8 | 0 | 8 | | 2023 | 12 | 0 | 12 | | 2024 | 3 | 1 | 4 | | 2025 | 8 | 1 | 9 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lupus Erythematosus, Systemic" by people in Profiles.
-
Irabu H, Ohara A, Nakamura A, Narazaki H, Hayashi Y, Yamasaki Y, Iwata N, Ohshima S, Nishiyama S, Nakagishi Y, Fukuhara D, Ishida H, Goto M, Hashimoto K, Yasuoka R, Nozawa T, Miyamae T, Umebayashi H, Mori M, Shimizu M. Validation of the 2019 EULAR/ACR classification criteria and clinical characteristics of childhood-onset Japanese patients with systemic lupus erythematosus. Mod Rheumatol. 2026 Mar 05; 36(2):239-245.
-
Olsen NJ, Liao D, James JA, Guthridge JM, Arriens C, Kamen D, Ishimori M, Wallace DJ, Striebich C, Narain S, Chong BF, He F, Schaefer EW, Chinchilli VM, Karp DR. A Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete Lupus. Arthritis Rheumatol. 2026 Apr; 78(4):870-879.
-
Munroe ME, Young K, Lu R, Guthridge JM, Kamen DL, Gilkeson GS, Weisman MH, Ishimori ML, Wallace DJ, Karp DR, Tsokos GC, Keith MP, Harley JB, Norris JM, James JA. Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activity. Lupus Sci Med. 2025 Nov 28; 12(2).
-
Rice MR, Matta B, Wang L, Luo Q, De Guzman J, Srinivasan D, Ludwig KR, Indukuri S, Brune L, Tan SL, Barnes BJ. TLR-induced STK25 activation promotes IRF5-mediated inflammation. Life Sci Alliance. 2025 09; 8(9).
-
van Dooren HJ, van Schaik M, Dorjée AL, Arends EJ, Mackay M, Cooney L, Fox DA, Wofsy D, Smilek D, Aranow C, Dall'Era M, Huizinga TWJ, van Kooten C, Toes REM, Diamond B, Teng YKO, Suurmond J. Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell-Targeting Treatment in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2025 Nov; 77(11):1560-1572.
-
Hayashi Y, Hatano M, Kaneko S, Shimbo A, Irabu H, Mori M, Shimizu M. Macrophage activation syndrome associated with neonatal lupus erythematosus. Lupus. 2025 Aug; 34(9):978-981.
-
Holers VM. Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases. Immunobiology. 2025 05; 230(3):152915.
-
Dhital R, Baer RJ, Kalunian K, Chambers C. Adverse pregnancy outcomes across SLE subgroups: significance of cardiovascular events. Lupus Sci Med. 2025 Apr 29; 12(1).
-
Shmizu M, Kaneko S, Shimbo A, Hatano M, Miyaoka F, Irabu H, Akutsu Y, Hayashi Y, Akamine K, Mori M. Anifrolumab for refractory cutaneous lupus lesions in pediatric systemic lupus erythematosus. Lupus. 2025 Apr; 34(5):533-536.
-
Timlin H, Koirala A, Gross M, Geetha D, Kamel I, Atta MG. Association of low-grade proteinuria with changes of lupus nephritis in kidney biopsy in SLE patients. Lupus. 2025 Apr; 34(4):331-336.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|